• Vertex agreed to acquire Crinetics in a merger, leaving Crinetics as a wholly owned Vertex subsidiary.
• Crinetics shareholders will vote on the deal at a special meeting scheduled for Aug. 28, 2026.
• Three shareholder lawsuits filed Aug. 6 and Aug. 17 allege the proxy materials were misleading, seeking to delay closing or win damages.
• Crinetics issued supplemental proxy disclosures on Aug. 18 to address the complaints and shareholder demand letters.
• The deal price is USD 85 per share, implying roughly USD 10 billion equity value.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Crinetics Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001140361-26-033738), on August 19, 2026, and is solely responsible for the information contained therein.